Omnes Capital's investments: Themis Bioscience

Sector 
Pharma
Entry Date 
05/2011
Business 
Venture Capital

Themis Bioscience

Next generation of prophylactic vaccines against emerging diseases

Themis Bioscience GmbH develops vaccines at the pre-clinical and early clinical stages.
The Vienna-headquartered company specialises in emerging tropical diseases. The first vaccine candidates currently under development target Chikungunya and Dengue fever. Themaxyn®, the innovative platform originally developed at the Pasteur Institute in Paris and protected by a number of patents, represents the vector for all the company’s current vaccine candidates.

 

Latest news